Three-Drug attack on breast cancer before surgery
NCT ID NCT04886531
Summary
This study is testing a combination of three drugs given to patients before breast cancer surgery. The goal is to see if this treatment can shrink tumors and potentially eliminate all detectable cancer by the time of surgery. It is for postmenopausal women with a specific type of breast cancer that is both hormone-sensitive and HER2-positive.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.